A leading company in promoting clinical transformation of biotherapeutic technologies
Unremitting efforts to improve human health
Shenzhen Beike Biotechnology Co., Ltd. (hereinafter referred to as “Beike Biotechnology”) was founded in July 2005, the company’s headquarters is located in the beautiful Shenzhen Bay, the coast of Houhai; At present, the company has more than 740 employees, of which more than 40% are technical research and development personnel. Beike Biotech is a national high-tech enterprise specializing in the clinical transformation and technical services of biotherapeutic technology in strategic emerging industries in China, and has a professional technical R&D team led by a number of expert-level domestic and foreign scholars with outstanding achievements in the field of cells.
As a leading company committed to promoting the clinical transformation of biotherapeutic technologies, Beike Bio has developed in the fields of biotechnology clinical transformation, stem cell basic research and clinical transformation for 19 years. Guided by the corporate philosophy of “loyalty, responsibility, rigor, innovation, care, service, teamwork and communication”, Beike Bio adheres to the core value of “quality is the lifeline of the enterprise” and insists on improving the company’s inherent strength through continuous scientific research innovation and quality management, thus gaining a good reputation and good reputation in the market.
Shenzhen Beike Biotechnology Co., Ltd. has passed the “three-in-one” management system certification of quality management system (ISO9001), environmental management system (ISO14001), and occupational health and safety management system (IOS 45001) for 14 consecutive years in terms of management system construction and expanded the scope of certification. It has also successfully completed the information security management system (IOS 27001) certification. At the same time, Beike Biotech Jiangsu Branch introduced and passed the comprehensive cell bank certified by the Association for the Advancement of Blood & Biotherapies (AABB, formerly the American Association of Blood Banks) in mainland China in 2012; In May 2017, Beike Biotech Shenzhen Cell Bank (Shenzhen Comprehensive Cell Bank) passed the AABB certification for the storage and application technology quality management system of four autologous cells (human umbilical cord-derived mesenchymal stem cells, human umbilical cord blood-derived hematopoietic stem cells, human placenta-derived mesenchymal stem cells, and human peripheral blood immune cells) at the same time.
The personalized cell therapy technology industry development model explored by Beike Biotechnology – “Regional Cell Preparation Center” has been named as the project of “Strategic Emerging Industry Regional Agglomeration Demonstration Project” by the National Development and Reform Commission. At present, the infrastructure for the industrialization of cell therapy – “Comprehensive Cell Bank + Regional Cell Preparation Center” has been deployed in South China, East China, Southwest China, Northwest China, North China, and Northeast China. This is based on the characteristics of individualization and instability constraints of cell therapy technology, “laying” a “cell therapy highway network” that can meet the timeliness of clinical needs and take into account the scale of production, connecting clinical needs and advanced technology suppliers, and building a standardized cell storage and preparation model that meets international standards and development trends.
Since its establishment, Beike Bio has always taken technological leadership and quality safety as its core competitiveness, attaches great importance to and continues to increase investment in research and development, so that the company can always maintain its leading position in technology in the industry. As of January 2024, Beike Bio has applied for 207 patents in the cell field, of which 162 have been authorized; published more than 100 papers in authoritative journals at home and abroad, including Cell Stem Cell; and undertaken more than 70 government projects at all levels, including 8 national projects (2 863 projects). Each cell “produced” by Beike Bio involves 680+ standard documents, 870+ quality records, and up to 910+ quality control node detection and confirmation, ensuring that each cell is traceable and traceable.
In June 2016, the “Cell Preparation Center Construction and Management Specifications” (No.: SZDB/Z 188-2016) jointly drafted by Shenzhen Municipal Market Supervision Administration, Shenzhen Municipal Development and Reform Commission, Shenzhen Beike Biotechnology Co., Ltd. and Shenzhen Institute of Standards and Technology was officially released; thereafter, the Shenzhen local standard “Comprehensive Cell Bank Construction and Management Specifications” (No.: SZDB/Z 266-2017) was officially released in September 2017. The release of the two local standards provides a useful reference for the formulation of my country’s cell therapy technology industry standards. The implementation of a series of specifications will surely lead and accelerate the process of the cell therapy industry entering the legalization, standardization and specialization. Beike Bio will take “comprehensive cell bank + regional cell preparation center” as the basis, “Internet +” as the means, and promote the cooperation of industrial investment funds to form a national individualized cell therapy industry public technology service platform and individualized cell therapy technology network.
In 2019, Beike Bio officially had the first batch of certified professional talents – cell preparation engineers and cell quality management engineers, and took the initiative to introduce a third-party professional cell quality testing platform to issue a legally binding test report for each tested cell, providing a reliable guarantee for the clinical application of cells.
Shenzhen Comprehensive Cell Bank was established by the Shenzhen Development and Reform Commission in accordance with the “Shenzhen Life and Health Industry Development Plan (2013-2020)” document to approve the “Shenzhen Beike Biotechnology Co., Ltd. to build Shenzhen Comprehensive Cell Bank” (Shenzhen Development and Reform [2014] No. 1717). It is a large platform for dealing with cell resources and applications. In the face of the current situation of inconsistent quality standards and information disconnection in the cell industry, Shenzhen Comprehensive Cell Bank has assumed the responsibility of establishing a platform with key common technologies such as third-party certification and development quality control, promoting the formulation of cell industry standards, and forming a traceable standardized information management system to provide technical services for Shenzhen’s life and health industry. As the infrastructure of Shenzhen’s life industry, Shenzhen Comprehensive Cell Bank has actively undertaken scientific research projects commissioned by relevant national and provincial and municipal departments, carried out relevant technical research, formulated important technical standards, and gathered and cultivated professional talents. With the new industrial development model of “Shenzhen Comprehensive Cell Bank + Regional Cell Preparation Center”, each family can provide cell preparation and cell resource preservation services that are synchronized with the international level.
In 2021, Beike Bio was awarded the honors of “Shenzhen Well-known Brand” and “Leading Enterprise in China’s Cell Field”; in 2022, Beike Bio was awarded the honor of “2022 Guangdong-Hong Kong-Macao Greater Bay Area Brand Influence Series-The Most Influential Brand of the Year”, and was recognized for its brand power.
The history of Beike Biotechnology
Beike is a Chinese biotechnology company with main offices in Shenzhen – located near to Hong Kong – and Taizhou. Our original development of stem cell therapies and their associated clinical applications began over twenty years ago. To date, over 60 leading PhD-qualified scientists from highly ranked Chinese universities contribute to advancing treatments offered by Beike. In addition to the scientists recruited from China, a significant proportion of our employees at Beike have previously worked at Western universities, including Stanford, the University of Minnesota, and UCLA.
The first patient to be treated with Beike processed cells was in 2001, who had been diagnosed with amyotrophic lateral sclerosis (ALS). From our founding, over 200 patients have participated in studies, with many showing discernable improvements in functioning following treatment. Beike was incorporated in July 2005 and has since provided partner hospitals with stem cells for the treatment of over 20,000 patients. Beike currently maintains 25 laboratories for both research and cell processing for clinical use and has received over US$6 million in funding from the government. During 2010, we were privileged to welcome the Chinese Premier Wen Jiabao for a tour of our facilities in Shenzhen.
Unlike many other stem cell treatment clinics, Beike prides itself on developing itself as a research organization. Our passion for helping patients extends beyond using stem cells for treatment based on research from other institutions. In addition to cell therapy, Beike has developed cell technologies and acts as a world leader in this important field. Development in this field has allowed Beike’s treatment protocols and stem cell processing to not only be guided by third-party research, but also aided in the internal development of our own cell therapies. Beike has almost 50 published peer-reviewed research papers in scientific journals around the world, such as Nature, and has spent in excess of ten million dollars over the past decade on cell therapy and research.
Since 2005, Beike has provided partner hospitals in China with stem cells for the treatment of over 20,500 patients. Beike currently provides more than 30 hospitals with umbilical cord, cord blood, and bone marrow-derived stem cells for the treatment of a variety of neurological and vascular conditions. As the sole developer and provider of stem cells to such hospitals, Beike is able to maintain full oversight over cell manufacturing, from the testing of blood products, to cell processing at our laboratories, to delivery of the cells for clinical use. This oversight and integrate process ensures exceedingly high safety and quality levels for patients. In addition, Beike also works closely with partner hospitals in modifying and advancing treatment protocols and patient care. Each partner hospital is equipped with on-hand Beike staff to assist patients both with treatment and general care during their hospital stay.
Beike concept
Loyalty
In the work, the company is put in the highest position in mind, highly agrees with the company's mission and vision, resolutely protects the company's interests and brand, and actively practices the company's philosophy and culture.
Accountability
Dare to take responsibility is the key to success, and the core lies in the sense of responsibility. Dare to stand up in the face of difficulties, dare to take responsibility in the face of mistakes, make a living from this, be proficient in this way, rack your brains, and exhaust all methods.
Strict
Every link and every detail must be kept improving, firmly establish the awareness that details determine success or failure, and be meticulous and do it right at one time.
Innovation
Innovation is the driving force for the development of science, we attach importance to the learning and accumulation of experience, and we need breakthroughs and progress. Technological innovation and concept innovation are our persistent core competitiveness.
Love
Caring between people is a kind of respect, a kind of spiritual communication, which helps to establish a common emotional experience and value orientation, harmony starts from care, and care starts from bit by bit.
Services
In the face of customers, we provide professional and attentive services; For partners, we provide win-win and mutually beneficial services. Service is our responsibility and our mission.
Teams
Cooperation is a concentrated embodiment of the overall situation awareness and the spirit of cooperation, which complements each other's advantages in sharing and mutual assistance, and exerts a positive synergistic effect in tolerance and gratitude, bringing the results of "1+1>2".
Ditch communication
Communication is conducive to establishing interpersonal relationships of mutual trust and eliminating mutual misunderstandings; It is conducive to creating a good working atmosphere and enhancing organizational cohesion; It is conducive to enhancing the centripetal force of the team and establishing a learning organization with a common vision.
Memorabilia of Beike
- The national standard “Technical Specifications for the Design of Cell Culture Clean Rooms” in which Beike Biotech participated was officially released
- Beike Biotech was approved to build the Shenzhen Academician (Expert) Workstation
- Beike Biotechnology introduced and deployed the first new fully automatic cell intelligent manufacturing system
- Beike Biotech won the title of “Shenzhen Famous Brand”
- The project “Drug Development of Mesenchymal Stem Cells for the Treatment of Novel Coronavirus Pneumonia” was approved as a key project of the Ministry of Science and Technology’s “Science and Technology to Promote Economy 2020”
- The project “Clinical Study on Human Umbilical Cord Mesenchymal Stem Cells for the Treatment of Severe Pneumonia Caused by Coronavirus” was approved by the Guangdong Provincial Department of Science and Technology’s “Guangdong Provincial Emergency Special Project for the Prevention and Control of New Coronavirus Infections”
- Beike Bio has successively issued two Shenzhen local standards: “Technical and Management Specifications for the Transportation of Human Living Samples” (No.: DB4403/T 120-2020) and “Technical and Management Specifications for the Transportation of Human Cell Products” (No.: DB4403/T 121-2020)
- The project in which Beike Biotech participated – “Key Technology Innovation and Clinical Application Research of Allogeneic Mesenchymal Stem Cells in the Treatment of Refractory Lupus Erythematosus” won the second prize of the National Technological Invention Award
- Beike Biotechnology was approved as the “Shenzhen Standardization Innovation Demonstration Base” again
- Beike Biotechnology was awarded the honor of “Model Enterprise for Synchronous Standardization and Innovation” in Shenzhen
- The “Integrated Cell Bank Setup and Management Specifications” (No.: SZDB/Z266-2017), jointly drafted by the Shenzhen Municipal Market Supervision Administration, Shenzhen Municipal Development and Reform Commission, Shenzhen Beike Biotechnology Co., Ltd. and Shenzhen Institute of Standards and Technology, was officially released.
- The four autologous cell storage application technology quality management systems of Beike Biotechnology Shenzhen Cell Bank (Shenzhen Comprehensive Cell Bank) (human umbilical cord-derived mesenchymal stem cells, human umbilical cord blood-derived hematopoietic stem cells, human placenta-derived mesenchymal stem cells, and human peripheral blood immune cells) have also passed AABB certification
- The “Cell Preparation Center Construction and Management Specifications” (No.: SZDB/Z 188-2016), jointly drafted by Shenzhen Municipal Market Supervision Administration, Shenzhen Municipal Development and Reform Commission, Shenzhen Beike Biotechnology Co., Ltd. and Shenzhen Institute of Standards and Technology, was officially released.
- Shenzhen Development and Reform Commission, Health and Family Planning Commission, and Market and Quality Supervision Administration jointly issued a document approving the establishment of Shenzhen (Beike Bio) Regional Cell Preparation Center
- “Beike Biotechnology Headquarters and International Stem Cell R&D Base” was completed and put into use
- Shenzhen Comprehensive Cell Bank and 11 Shenzhen municipal and district-level medical institutions jointly established a clinical transformation network
- Shenzhen Development and Reform Commission issued a document approving Beike Biotechnology to establish the Shenzhen Comprehensive Cell Bank, and Beike Biotechnology will be responsible for subsequent operations
- Approved to establish Shenzhen Postdoctoral Innovation and Practice Base
- “2013-068: Key technology research and development of mesenchymal stem cell injection for the treatment of systemic lupus erythematosus” was listed as a major technical research project by Shenzhen Innovation Committee
- Two stem cell technologies of Jiangsu Branch of Beike Biotechnology have passed AABB certification
- The “Tissue Engineering and Stem Cell Special Project” in the “Shenzhen Bio-Industry Revitalization and Development Plan (2009-2015)” specifically proposes “promoting the construction of the Beike Bio-Stem Cell and Regenerative Medicine Industrialization Project”
- Rylea, a blind American child with congenital optic nerve hypoplasia, regained her sight with the help of stem cell technology from Beike Biotech
- Business Weekly of the United States commented that Beike Biotechnology “is looking for the forefront of stem cell technology, not in Cambridge, Stanford or Singapore, but in Shenzhen, China”
- Shenzhen Beike Biotechnology Co., Ltd. was established
Platform Authorization
The development of Beike Bio’s cell industry has been strongly supported
by the Ministry of Science and Technology, the National Development and Reform Commission and many provincial and municipal governments at all levels, and the stem cell and regenerative medicine industry projects of Beike Biotechnology have been included in the key breakthrough projects of various industries
Beike Qualification/Patent
As of January 2024, Beike Biotech has applied for 207 patents in the field of cells, of which 162 have been authorized
to publish more than 100 papers
in authoritative journals at home and abroad, including Cell, Stem Cell, etc., and undertake more than 70 government projects at all levels, including 8 national projects (2 863 projects)
